MAM
XFOR icon

Meeder Asset Management’s X4 Pharmaceuticals XFOR Stock Holding History

Meeder Asset Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-16
Closed -$5K – 2516
2020
Q1 		$5K Buy
+16
New +$4.54K ﹤0.01% 1816
2019
Q3 		– Sell
-7
Closed -$3K – 2276
2019
Q2 		$3K Sell
7
-6
-46% -$3.05K ﹤0.01% 1817
2019
Q1 		$7K Buy
13
+5
+63% +$2.76K ﹤0.01% 1332
2018
Q4 		$3K Sell
8
-33
-80% -$12.6K ﹤0.01% 1531
2018
Q3 		$11K Buy
+41
New +$17.4K ﹤0.01% 1145

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's XFOR Position: Q2 2020 in Review

Meeder Asset Management sold out of X4 Pharmaceuticals (XFOR) in Q2 2020, closing a stake of 16 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in XFOR in Q3 2018 and held it in 5 quarters. The position peaked at $11K in Q3 2018. 57 funds tracked by Wall St. Rank hold XFOR as of Q2 2020.

  • Meeder Asset Management reported no remaining X4 Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Meeder Asset Management sold 16 X4 Pharmaceuticals shares in Q2 2020, an estimated $5K.
  • Meeder Asset Management first reported a position in X4 Pharmaceuticals in Q3 2018 and held it in 5 quarters.
  • Meeder Asset Management's X4 Pharmaceuticals position peaked at $11K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.